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Abstract
 
Full activation of naive T cells requires both engagement of the T cell antigen receptor (TCR;
signal 1) and costimulatory signaling by CD28 (signal 2). We previously identified two types of
rat CD28-specific monoclonal antibodies (mAbs): “conventional,” TCR signaling–dependent
costimulatory mAbs and “superagonistic” mAbs capable of inducing the full activation of pri-
mary resting T cells in the absence of TCR ligation both in vitro and in vivo. Using chimeric
rat/mouse CD28 molecules, we show that the superagonists bind exclusively to the laterally
exposed C
 
  
 
D loop of the immunoglobulin-like domain of CD28 whereas conventional, co-
stimulatory mAbs recognize an epitope close to the binding site for the natural CD80/CD86
ligands. Unexpectedly, the C
 
  
 
D loop reactivity of a panel of new antibodies raised against hu-
man CD28 could be predicted solely on the basis of their superagonistic properties. Moreover,
mouse CD28 molecules engineered to express the rat or human C
 
  
 
D loop sequences activated
T cell hybridomas without TCR ligation when cross-linked by superagonistic mAbs. Finally,
biochemical analysis revealed that superagonistic CD28 signaling activates the nuclear factor 
 
 
 
B
pathway without inducing phosphorylation of either TCR
 
  
 
or ZAP70. Our findings indicate
that the topologically constrained interactions of anti-CD28 superagonists bypass the require-
ment for signal 1 in T cell activation. Antibodies with this property may prove useful for the
development of T cell stimulatory drugs.
Key words: costimulation • CD28 • T cells • lymphocyte activation • receptor structure
 
Introduction
 
Ligation of the T cell surface receptor CD28 is the most
powerful way to costimulate resting T cells, turning nonpro-
ductive or even anergizing signals that result from TCR
stimulation alone, into fully activating signals (1, 2). In ex-
perimental systems, the natural ligands of the TCR, the cog-
nate MHC–peptide complexes, and of CD28, the B7 family
members CD80 and CD86, can be replaced by mAbs, which
bind to and cross-link the TCR and CD28, respectively.
The mechanism by which TCR- and CD28-derived
 
signals are integrated are not completely understood. In
addition to a downstream convergence of signaling cas-
cades (3), current models postulate a cross talk between the
two receptors at the cell membrane. Thus, costimulation
triggers polarized transport of membrane domains rich in
signaling molecules toward the T cell APC contact area (4,
5). Furthermore, CD28 colocalizes with the TCR at the
center of the mature immunological synapse (also called the
 
central supramolecular activation cluster [c-SMAC];
 
*
 
 refer-
ences 6–8), wherein CD28 engagement is proposed to en-
hance and sustain early signaling by the TCR (4, 9, 10).
Together, these findings suggest that costimulation pro-
motes mature synapse formation and that in the synapse it-
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Abbreviations used in this paper: 
 
aa, amino acid(s); c-SMAC, central su-
pramolecular activation cluster; EPO, erythropoietin; NF, nuclear factor.T
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self, CD28 amplifies TCR signaling. More recent studies
indicate, however, that synapse formation per se occurs in-
dependently of costimulation (6) and that the mature im-
munological synapse (with CD28 at the c-SMAC) is
formed after TCR signaling has largely subsided (11).
Thus, TCR stimulation (signal 1) now appears to create a
microenvironment, the c-SMAC, which favors the interac-
tion of CD28 with its ligands, leading to secondary signal-
ing (i.e., signal 2; reference 6).
Based on experiments using mAbs raised against CD28,
we previously proposed a two-step mechanism for costim-
ulation (12). Specifically, we showed that rat CD28-spe-
cific mAbs fall into two functionally distinct categories:
“conventional” mAbs, which are agonists only in the pres-
ence of coincident TCR ligation, and “superagonists,”
which fully activate primary resting T cells in vitro and in
vivo without signal 1 (12). Because the availability of the
epitope recognized by superagonistic mAbs is strongly up-
regulated by TCR stimulation (13), we hypothesized that
superagonistic CD28-specific mAbs may recognize and re-
cruit a distinct subset of CD28 molecules that are more sig-
naling competent. Thus, similar to the mechanism now
proposed as a likely scenario at the immunological synapse,
these results suggested a mechanism for costimulation in
which TCR stimulation (signal 1) alters the molecular en-
vironment of CD28, favoring secondary signaling by the
clustered, signaling-competent subset of CD28 molecules
(signal 2).
If the clear-cut functional differences between conven-
tional and superagonistic CD28-specific mAbs are a reflec-
tion of the dynamic changes in supramolecular receptor re-
organization during T cell activation, a precise definition of
the binding sites of conventional and superagonistic mAbs
on the CD28 molecule should provide clues about this
physiological process. In this report, we have mapped the
binding sites of superagonistic and conventional rat and hu-
man CD28-specific mAbs. We show that the superagonists
bind to the laterally exposed C”D loop of the extracellular
Ig-like domains of the CD28 homodimer whereas conven-
tional anti-CD28 mAbs bind at or close to the B7 binding
site, therein suggesting mechanisms for the differential ef-
fects of costimulatory and superagonistic mAbs.
We have previously shown in the rat model that super-
agonistic CD28-specific mAbs are highly potent stimulators
of T cell proliferation in vivo without apparent toxicity
(12, 14). The identification of the conserved structural basis
of “direct” CD28-driven T cell activation in rodents and
humans by superagonistic ligands should now facilitate the
therapeutic exploitation of mitogenic and anti-apoptotic
CD28 signaling in immunopathologies characterized by T
cell deficiencies.
 
Materials and Methods
 
Antibodies.
 
The generation of the mAbs JJ316 and JJ319 has
been previously described (12, 15). The other anti–rat CD28
mAbs used in this study originated from these published experi-
ments but had not yet been characterized in detail. Anti–mouse
 
CD28 (clone 37.51; reference 16), mouse anti–phosphotyrosine
(clone 4G10), and mouse anti–human CD3 (clone UCHT1) was
purchased from BD Biosciences. Mouse anti–human TCR
 
 
 
(clone 6B10.2) and rabbit polyclonal antibodies to nuclear factor
(NF)-
 
 
 
B p50, c-rel, and USF-2 were from Santa Cruz Biotech-
nology, Inc., and mouse anti–human ZAP-70 (clone 3.3.1; refer-
ence 17) was provided by A.D. Beyers (University of Stellen-
bosch, Matieland, South Africa). The generation of the anti–rat
TCR mAb R73 was previously described (18).
 
Generation of mAbs Specific for Human CD28.
 
BALB/c mice
were immunized repeatedly intraperitoneally with recombinant
human CD28-Fc fusion protein and a CD28-transfected B lym-
phoma cell line. 3 d before cell fusion, animals were boosted in-
travenously. Fusion of spleen cells from immunized mice and
X63Ag8.653 myeloma cells was performed by polyethylene gly-
col treatment according to standard protocols (15). Routinely,
hybridoma cells secreting CD28-specific mAbs were subcloned
once. Superagonistic anti-CD28 mAbs were subcloned twice.
 
Animals.
 
Lewis rats and C57BL/6 mice were bred at the In-
stitute for Virology and Immunobiology, University of Würz-
burg. Mesenteric lymph nodes were taken from young adult ani-
mals and single cell suspensions were used for FACS
 
® 
 
analysis and
T cell proliferation assays.
 
Cloning of DNA Constructs.
 
The rat CD28 cDNA (15, 19)
was inserted into the cloning vector Bluescript pBS KS (
 
 
 
). Se-
quence analysis revealed that amino acid (aa) at position 85 is
identical to the homologue mouse CD28 aa in contrast to the
data bank (NCBI protein) information. Mouse CD28 cDNA was
amplified from whole mouse lymph node cDNA using
5-GCGTCGACGGCCCTCATCAGAACAATGAC-3
 
  
 
as the
sense primer and 5-GGAAGCTTCCCTGTCAGGGGCGG-
TACGCT-3
 
  
 
as the antisense primer and then cloned into the
pCR 3-uni-expression vector (Invitrogen) or the cloning vector
Bluescript pBS KS (
 
 
 
).
To generate the r/mCD28 1–37, the EcoNI/XhoI mouse
CD28 cDNA fragment was cloned into the corresponding
EcoNI/XhoI site present in the rCD28 sequence in pBS KS (
 
 
 
).
The resulting chimeric construct was then cloned into the ex-
pression vector pCR 3-uni. The chimeric construct m/rCD28 1–
37 was generated by inserting the EcoNI/XhoI rat CD28 cDNA
fragment into the corresponding EcoNI/XhoI site present in
mCD28 in pBS KS (
 
 
 
) and then cloned into the pCR 3-uni ex-
pression vector.
For the m/r CD28 1–66 construct, the rat part of the chimeric
molecule was amplified by PCR using 5
 
 
 
-TCGCTCGAATGC-
CGAGTTCAACTGTGATGG-3
 
  
 
as the sense and 5
 
 
 
-
TTTTGCTCGAGCCCTGTCAGGGGCGGTACG-3
 
  
 
as the
antisense primer and cloned into the Mva1269I/XhoI site present
in mCD28 in pBS KS (
 
 
 
). The chimeric construct was then sub-
cloned into the expression vector pH
 
 
 
APr-1-neo, as this vector
exhibited a higher transfection efficiency in L929 cells compared
with pCR 3-uni.
All point mutants were generated using the Quick Change kit
(Stratagene) according to the manufacturer’s instructions. The
following primers were used: mCD28 A64V, E65G: sense
5
 
 
 
-CCCAGTTTCGCTCGAATGTGGGGTTCAACTGCGA -
CGGG-3
 
 
 
, antisense 5
 
 
 
-CCCGTCGCAGTTGAACCCCACA-
TTCGAGCGAAACTGGG-3
 
 
 
; mCD28 S62P, A64V, E65G:
sense 5
 
 
 
-CCAGTTTCGCCCAAATGTGGGGTTCAA-3
 
 
 
,
antisense 5
 
 
 
-TGGAACCCCACATTTGGGCGAAACTGG-3
 
 
 
;
mCD28 S62P, A64V, E65G, D71N: sense 5
 
 
 
-AACTGCG-
ACGGGAATTTCGACAA-3
 
 
 
, antisense 5
 
 
 
-TTGTCGAAAT-
TCCCGTCGCAGTT-3
 
 
 
; mCD28 S62P, A64V, E65G, D71N,T
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R109K: sense 5
 
 
 
-GACAACGAGAAGAGCAATGGAACT-3
 
 
 
,
antisense 5
 
 
 
-AGTTCCATTGCTCTTCTCGTTGTC-3
 
 
 
; mCD28
S62P, A64V, E65G, D71N, R109K, F98V: sense 5
 
 
 
-TGC-
AAAATTGAGGTCATGTACCCTC-3
 
 
 
, antisense 5
 
 
 
-GAGGG-
TACATGACCTCAATTTTGCA-3
 
 
 
; mCD28 S62P, A64V,
E65G, D71N, T125A, S127T: sense 5
 
 
 
-TCTTTGTCATGCT-
CAGACGTCTCCTAAGC-3
 
 
 
, antisense 5
 
 
 
-GCTTAGGAG-
ACGTCTGAGCATGACAAAGA-3
 
 
 
; mCD28(h) F60V, R61T,
N63K, A64T, E65G: sense 5
 
 
 
-CCCAGTTTCGCTCGAAAA-
CGGGGTTCAACTGCGA-3
 
 
 
, antisense 5
 
 
 
-TCGCAGTTGA-
ACCCCGTTTTCGAGCGAAACTGGG-3
 
 
 
, as well as sense
5
 
 
 
-TATCAGCCCCAGGTTTACTCGAAAACGG-3
 
 
 
, antisense
5
 
 
 
-CCGTTTTCGAGTAAACCTGGGGCTGATA-3
 
 
 
. All point
mutants were cloned into the expression vector pH
 
 
 
APr-1-neo.
The correct generation of all chimeric constructs and point mu-
tants was verified by sequencing.
The constructs mCD28 S62P, A64V, E65G and mCD28(h)
F60V, R61T, N63K, A64T, E65G were amplified using the
primers sense 5
 
 
 
-GCGCCAATTGCCCTCATCAGAACAA-
TGAC-3
 
  
 
and antisense 5
 
 
 
-ATTTCGGATCCTGTCAGGG-
GCGGTACGCT-3
 
  
 
and then cloned into the EcoRI/BamHI
site of the retroviral pczCFG5 IZ vector. This is a derivative of
the described pEYZ/MCS retroviral vector (20) in which the
open reading frame coding for the EYFP-zeocin fusion protein
was removed and an IRES/zeomycin cassette introduced instead.
As control, a construct was used that contained the extracellular
domain of rat CD28 coupled to the transmembrane and cytoplas-
mic domain of mouse CD28 (hereafter referred to as extracellular
WT rat CD28). For this, the mouse part of the molecule was am-
plified using the primers sense 5
 
 
 
-TGCTCAGACGTCTC-
CTAAGCTGTTTT-3
 
 
 
, antisense 5
 
 
 
-GGAAGCTTCCCTGT-
CAGGGGCGGTACGCT-3
 
  
 
and the PCR product was cloned
into the AatII/HindIII site of rat CD28 in Bluescript pBS KS
(
 
 
 
). The chimeric construct was cloned into the EcoRI site of
pczCFG5 IZ.
 
Expression of Constructs in Cell Lines.
 
The constructs in the
expression vectors pCR 3-uni or pH
 
 
 
Apr-1-neo were stably
transfected into L929 cells using lipofectamin (Life Technologies)
according to the manufacturer’s recommendations. Transfected
cells were selected using RPMI 1640 medium (5% FCS; Life
Technologies) containing G418 (Pan Biotech GmbH) at a final
concentration of 1 mg/ml. After 2 wk of selection the percentage
of cells expressing the appropriate construct ranged between 30
and 90%. If the transfection efficiency was low (as the case for
m/r CD28 1–66, mCD28 S62P, A64V, E65G and mCD28
S62P, A64V, E65G, D71N, R109K), the transfected cells were
stained with anti-CD28 and positive cells were sorted using a
FACSVantage™ cell sorter (Becton Dickinson) and further prop-
agated in RPMI 1640 medium containing G418.
The TCR
 
  
 
58 mouse T cell hybridoma (21) was first retrovi-
rally transduced with a rat myelin basic protein-specific TCR
(provided by T. Herrmann, University of Würzburg, Würzburg,
Germany, and Herrmann, T., personal communication). The
CD28 constructs in the retroviral vector pczCFG5 IZ were then
introduced into these cells using retroviral infection. Recombinant
retroviral vector supernatants were generated by cotransfection
with vectors encoding VSV-G and pHIT 60 as previously de-
scribed (22, 23). 
 
 
 
90% of the cells were positive for the expression
of the appropriate molecules when tested by FACS
 
® 
 
analysis.
 
FACS
 
® 
 
Analysis.
 
For FACS
 
® 
 
analysis, 5 
 
  
 
10
 
5 
 
cells were re-
suspended in PBS/0.1% BSA/0.02% NaN
 
3 
 
and incubated for 30
min with 0.5 
 
 
 
g purified antibody (for JJ316 and JJ319) or 100 
 
 
 
l
culture supernatant (for all other anti–rat CD28 mAb) on ice fol-
 
lowed by development with PE-labeled donkey anti–mouse IgG
(Dianova). Flow cytometric analysis was performed with a FAC-
Scan™ flow cytometer (Becton Dickinson) and CellQuest™
software using logarithmic amplification of fluorescence signals
from scatter-gated live cells.
 
T Cell Proliferation Assays.
 
Rat T cells were purified from
lymph node cell suspensions by nylon wool passage. Routinely,
T cells were enriched to 
 
 
 
90% by this method whereas B cells
and monocytes were efficiently depleted and made up 
 
 
 
1% of
the cell suspension. 10
 
5 
 
purified T cells were used for the prolifer-
ation assay using either costimulatory conditions (immobilized
anti-TCR mAb R73 and soluble anti-CD28 mAb) or mitogenic
conditions (immobilized sheep anti–mouse Ig plus anti-CD28;
references 12 and 13). Proliferation was determined by [
 
3
 
H]thy-
midine incorporation.
Human T cells from freshly drawn peripheral blood were ob-
tained from ficoll-purified PBMC and nylon wool passage. Rou-
tinely, purity was 
 
 
 
90%. Cells were adjusted to 5 
 
  
 
10
 
5
 
/ml and
cultured in RPMI 1640 medium containing 10% autologous se-
rum in 200 
 
 
 
l final volume in 96-well plates (Costar) that had
previously been coated with 40 
 
 
 
g/ml donkey anti–mouse Ig an-
tiserum (Dianova), followed by extensive washing and incubation
with 0.003 
 
 
 
g/ml anti-CD3 mAbs (costimulation) or without
anti-CD3 mAbs (direct stimulation) for 15 min on ice. After
washing, soluble anti-CD28 mAbs were added to the cultures at a
final concentration of 3 
 
 
 
g/ml (see Fig. 4, A and B) or as indi-
cated (see titration in Fig. 4 C). As positive control, cells were
stimulated with 5 
 
 
 
g/ml PHA and 200 U/ml IL-2. After 72 h,
proliferation was measured by [
 
3
 
H]thymidine incorporation.
 
Stimulation of 58 T Hybridoma Cells and IL-2 Measurement.
 
58
T hybridoma cells (21) transfected with either extracellular WT
rat CD28, mCD28 S62P, A64V, E65G or mCD28(h) F60V,
R61T, N63K, A64T, E65G were stimulated with either plate-
coated anti-TCR mAb, a mitogenic anti-CD28 mAb (JJ316 for
rat, 5.11A1 for human), a nonmitogenic anti-CD28 mAb (JJ319
for rat, 37.51 for the chimeric molecules), both at final concen-
trations of 10, 5, 2.5, and 1 
 
 
 
g/ml, or left untreated. After 2 d,
the IL-2 content in the supernatant was tested using an Opti EIA
mouse IL-2 detection kit (BD Biosciences) according to the
manufacturer’s instructions.
 
Modeling of the Mouse CD28 Structure.
 
The human CD28
monomer was modeled on the murine CTLA-4 structure (24)
using the sequence alignment derived by Metzler et al. (25) and
the program O (26). The dimer was constructed on the basis of
the CTLA-4 homodimer observed in the crystals of the complex
of human CTLA-4 and CD80 (26). Fig. 3 was drawn using
BOBSCRIPT (27).
 
Stimulation, Immunoprecipitation, and Preparation of Nuclear Ex-
tracts.
 
T cells obtained by leukopheresis were purified to 
 
 
 
90%
purity by nylon wool passage. 108 cells were incubated for 1 h at
4 C with 5  g/ml conventional (7.3B6) or mitogenic anti-CD28
(5.11A1) antibodies, or a mixture of 5  g/ml anti-CD3 (OKT3)
and 0.5  g/ml conventional anti-CD28 antibodies. Cells were
washed, incubated for 30 min at 4 C with 10  g/ml rat anti–
mouse IgG, and incubated for 0.5 min at 37 C before the addi-
tion of NP-40 lysis buffer (final concentration 1% NP-40, 25
mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1 mM pe-
fabloc, 5 mM iodoacetamide, 1 mM Na3VO4, 1 mM NaF).
Lysates were centrifuged (14,000 rpm for 10 min at 4 C) and
the supernatant was added to protein G–Sepharose precoated
with 5  g ZAP-70 and TCR  antibody. Beads were incubated
with rotation for 2 h at 4 C, washed four times with lysis
buffer, and samples were resolved by SDS-PAGE and WesternT
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blotted. Membranes were probed with anti-phosphotyrosine
antibody and reprobed with antibodies to TCR  and ZAP-70
to ensure comparable loading. For preparation of nuclear ex-
tracts, 2   107 cells were stimulated for 20 h on sheep anti–
mouse IgG-coated plates as previously described (13) and the
protocol of Schreiber et al. (28) was followed. Protein con-
centration was measured using the Bradford assay (Bio-Rad
Laboratories) and 6  g protein per lane was resolved by SDS-
PAGE, Western blotted, and probed with antibodies to c-Rel
and USF-2.
Results
Activity of Conventional and Superagonistic Rat CD28-spe-
cific mAbs. We had previously isolated nine mouse IgG1/ 
mAbs to rat CD28 and characterized the functional activity
of two representative clones: JJ319 is a conventional, i.e.,
TCR stimulation–dependent mAb whereas JJ316 is a su-
peragonistic, i.e., autonomously mitogenic CD28-specific
antibody (12, 15). To perform structure function analyses
with a broader panel of mAbs, the activity of all nine anti-
bodies was tested on freshly isolated rat lymph node T cells
in the presence and absence of TCR ligation. As shown in
Fig. 1, all nine antibodies were potent costimulators of T
cell proliferation in cultures containing immobilized TCR-
specific mAbs. As expected, the majority of these mAbs
(seven out of nine) were completely ineffective if signal 1,
i.e., TCR stimulation, was omitted. However, two of
these antibodies, the previously described superagonist
JJ316 and the mAb 5S38.17, triggered strong T cell prolif-
eration without TCR engagement. Thus, the nine rat
CD28-specific mAbs analyzed fell into two categories:
conventional (7) and superagonistic (2).
Separation of Epitopes Recognized by Conventional and
Superagonistic CD28-specific mAbs. The extracellular do-
mains of mouse and rat CD28 differ at only nine aa posi-
tions (Fig. 2 A). Because our mouse mAbs to rat CD28 did
not bind to mouse CD28 (unpublished data), mouse/rat
CD28 chimeras were generated and tested for mAb bind-
ing. Initially, the prototypic mAbs, JJ319 (conventional)
and JJ316 (superagonistic), were used for binding studies
and the hamster anti–mouse CD28 mAb 37.51 (16) was in-
cluded as an expression control for constructs that had lost
binding of rat CD28-specific mAbs.
To narrow down the region containing the epitope(s)
recognized by JJ319 and JJ316, chimeric proteins were
generated in which either the aminoterminal one third (aa
1–37) of extracellular mouse CD28 was replaced with the
corresponding region of the rat molecule (r/m CD28
1–37) or vice versa (m/r CD28 1–37). In addition, a chi-
meric molecule was generated in which the aminoterminal
half (aa stretch 1–66) of extracellular rat CD28 was replaced
with the corresponding mouse sequence (m/r CD28
1–66). In each case, the transmembrane region and the cy-
toplasmic tail were derived from the backbone molecule as
defined by the extracellular region closest to the transmem-
brane domain (Fig. 2). L929 fibroblast cells were transfected
with these chimeric molecules, resulting in expression rates
ranging from 30–90%, and binding of CD28-specific mAbs
was determined by flow cytometry.
As shown in Fig. 2 B, rows 1–3, superagonist (JJ316)
binding mapped to the stretch of aa 37–66 located in the
middle of the extracellular rat sequence whereas the
epitope recognized by the conventional mAb JJ319 is lo-
cated between aa 66 and the transmembrane domain. Fur-
thermore, the conventional mouse CD28-specific mAb
37.51 binds to an epitope in the orthologous region
(downstream of aa 66) of mouse CD28.
The Superagonistic mAb JJ316 Recognizes the C  D Loop of
Rat CD28. Within the stretch of aa 37–66, defined
above as critical for superagonist mAb binding, mouse and
rat CD28 differ at three positions (aa 62, 64, and 65), all of
which are located within the C  D loop of the proposed
CD28 structure as modeled on the CTLA-4 crystal struc-
ture (Fig. 3). Stepwise introduction of these three rat-spe-
cific aa into mouse CD28 confirmed the requirement for
the complete rat-specific C  D sequence for full superago-
nist binding (Fig. 2 B, rows 4 and 5).
The Conventional CD28-specific mAbs JJ319 and 37.51
Bind Near the B7 Binding Site. To also define the epitope
seen by the conventional mAb JJ319, single aa that differ
between rat and mouse CD28 in the region between aa 66
and the transmembrane region were additionally mutated.
Figure 1. Costimulation and direct stimulation of pri-
mary rat T cells by rat CD28-specific mAb. (A) Nylon
wool–purified rat lymph node T cells (105/well) were
stimulated by anti-TCR mAb R73 immobilized via sheep
anti–mouse IgG and soluble rat CD28-specific mAb. An
isotype-matched irrelevant mAb served as negative control
for the CD28-specific mAb. On day 3, the cells were
pulsed with 0.5  Ci [3H]thymidine per well for 16 h fol-
lowed by harvesting and   counting. (B) As in A but with-
out anti-TCR mAb. One representative experiment from
two with the identical outcome is shown.T
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First, aspartic acid was changed to asparagine at position 71.
This mutation failed, however, to restore binding of JJ319
(not depicted). The same was true when another mouse-
specific aa, arginine at position 109, was changed to lysine
as found in rat CD28 (Fig. 2 B, row 6). In contrast, when
the remaining mouse-specific aa phenylalanine at position
98 was changed to valine, the binding of JJ319 was indis-
tinguishable from that of JJ316 (Fig. 2 B, row 7). There-
fore, valine at position 98 is critical for the epitope recog-
nized by the conventional rat CD28-specific mAb JJ319.
Interestingly, the binding of the conventional anti–
mouse CD28 mAb 37.51 was inversely related to that of
the rat-specific mAb JJ319. Thus, 37.51 binding was lost
when at position 98, the mouse-specific aa phenylalanine
was changed to valine (Fig. 2 B, row 7). In an additional
construct (not depicted), the remaining two extracellular
mouse-specific aa that are located in close proximity to the
transmembrane region (aa 125/127) were mutated to the
rat sequence instead of aa 98. These mutations did not re-
sult in binding of the rat CD28-specific mAb JJ319 or in
loss of binding of the mouse CD28-specific mAb 37.51.
Therefore, these two conventional mAbs recognize an
epitope at or near aa 98 and thus close to the B7 binding
site (29).
Correlation between Epitope Binding and Mitogenicity of
mAbs. To test whether the structure function relationship
established for the superagonistic mAb JJ316 and the con-
ventional mAbs JJ319 and 37.51 can be generalized, the
second superagonist and the remaining six conventional rat
CD28-specific mAbs (Fig. 1) were tested for binding to the
various mouse/rat hybrid molecules. Only one antibody,
5S38.17, reacted with L929 cells expressing mouse CD28
with the grafted rat C  D loop but did not bind to the m/r
CD28 1–66 molecule. It therefore reproduces the binding
characteristics of JJ316 (Table I). The other six mAbs, de-
fined as conventional by function, also displayed the same
binding characteristics as the conventional mAb JJ319, in-
cluding a requirement for the rat-specific valine at position
98. Thus, both superagonistic mAbs recognized the C  D
loop whereas all seven conventional mAbs isolated bind to
an epitope near the B7 binding site.
Human CD28-specific Superagonistic mAbs Also Bind to the
C  D Loop. Because superagonistic CD28 stimulation
provides an attractive approach to stimulatory immuno-
Figure 2. Epitope mapping of a superagonistic (JJ316)
and conventional (JJ319) rat CD28-specific mAb. (A)
Comparison of extracellular portions of mouse and rat
CD28. Positions of aa differences are indicated by num-
bers. (B) Binding of superagonistic and conventional mAbs
to rat/mouse CD28 chimeras. Mouse sequences are repre-
sented in white and rat sequences in black. Positions of
swapped aa are indicated on the left. All constructs were
stably expressed in L929 fibroblast cells. FACS® histograms
are shown for superagonistic (JJ316) and conventional
(JJ319) rat and for the conventional mouse CD28-specific
mAb 37.51 (solid lines) and an isotype-matched control
mAb (dotted lines). At least two independent experiments
were performed and a representative experiment is shown.T
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therapy, a set of novel human CD28-specific mAbs was
generated and tested for TCR-dependent and -indepen-
dent induction of proliferation of primary human T cells.
Initial screening of 24 CD28-specific mAbs identified two
superagonists, 9D7 and 5.11A1, which were purified and
functionally tested in parallel with a representative conven-
tional anti-CD28 mAb, 7.3B6. As shown in Fig. 4, the
clear-cut functional difference between conventional and
superagonistic mAbs described above for rat CD28 was re-
produced for the human system. Thus, in the absence of
Figure 3. Depiction of the epitopes for superagonistic and conventional CD28-specific mAbs in a three-dimensional model of the extracellular part of
human CD28. The model of the CD28 monomer was derived by computer calculation from the X ray crystallographic structure of murine CTLA-4 us-
ing the sequence alignment derived by Metzler et al. (reference 25). The dimer was constructed on the basis of the CTLA-4 homodimer observed in the
crystals of the complex of CTLA-4 and CD80, and is shown with the membrane-proximal region at the top. The MYPPPY motif (aa 99–104) critical for
B7 binding is indicated in green, the adjacent aa 98 residue critical for binding of the conventional rat and mouse CD28-specific mAb is highlighted in
yellow, and the C  D loop responsible for the binding of superagonistic rat and human CD28-specific mAb (aa 60–65) is indicated in red.
Table I. Reactivity of Rat CD28-specific mAb with Mouse and Rat CD28 as well as Different Chimeric and Mutant CD28 Molecules
Antibody
Mouse
CD28
Rat
CD28
m CD28
S62P, A64V,
E65G
m/r CD28
1-66
m CD28 S62P, A64V,
E65G, D71N, R109K
m CD28 S62P, A64V,
E65G, D71N, R109K, F98V
control           
37.51                  
JJ316                    
JJ319                  
5S28               
5S38.17                
5S247                  
5G40/2                  
5G87               
5G111               
5S35                  
   , very strong reactivity in FACS® analysis;   , strong reactivity;  , weak reactivity;  , no reactivity. As controls, an isotype-matched irrelevant
mAb and the mouse CD28-specific 37.51 mAb were included.T
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961 Lühder et al.
TCR/CD3 ligation, mAbs 9D7 and 5.11A1 induced
strong proliferation in freshly isolated human T cells
whereas the stimulatory activity of mAb 7.3B6 was strictly
dependent on the presence of immobilized anti-CD3 mAb.
Although mouse and rat CD28 share 93% sequence
identity in the extracellular part of the molecule, human
CD28 is only 65% identical to the mouse sequence. Ac-
cordingly, instead of mapping the epitopes for all human
CD28-specific mAbs, we directly tested the hypothesis that
the C  D loop identified as the epitope for the superagonis-
tic rat CD28-specific mAb is also the target for the novel
human CD28-specific superagonistic mAb. As shown in
Fig. 5, this was indeed the case. Thus, grafting of the hu-
man C  D loop to the mouse backbone by mutating 5 aa
rendered mouse CD28 fully reactive with the superagonis-
tic mAbs 9D7 and 5.11A1, but not with the conventional
mAb 7.3B6.
mAb Binding to Grafted Rat or Human C  D Loops Results
in Superagonistic Responses. Next, we wanted to know
whether in the heterologous environment of mouse CD28,
engagement of the C  D loop by human or rat CD28-spe-
cific mAbs is sufficient to induce a superagonistic response.
To this end, mouse CD28 molecules in which the C  D
loop had been changed either to the rat sequence by three
or to the human sequence by five aa exchanges were intro-
duced into the mouse T cell hybridoma 58 (21), previously
transfected with a rat TCR. As a positive control, a chi-
meric CD28 protein was expressed in which the whole ex-
tracellular part consisted of rat CD28 and the rest of the
molecule was mouse CD28.
When these transfectants were stimulated via the TCR,
they produced substantial amounts of IL-2 (Fig. 6). Impor-
tantly, IL-2 production was also efficiently induced when
the cells were exclusively stimulated via CD28 using super-
agonistic anti-CD28 mAbs in a dose-dependent manner.
Ligation of these chimeric CD28 molecules by conven-
tional anti-CD28 (JJ319 for rat CD28, the mouse CD28-
specific mAb 37.51 for the C  D loop grafted molecules)
did not induce IL-2 production at any concentration
tested. This result clearly shows that targeting mAb binding
to the C  D loop of the mouse CD28 molecule leads to a
superagonistic response even in this heterologous setting.
Superagonistic CD28 Signaling Induces NF- B Activation,
but not TCR  nor ZAP-70 Phosphorylation. To further ex-
plore the mechanism of superagonistic CD28 signaling,
purified peripheral human T cells were stimulated by co-
stimulation or using superagonistic or conventional CD28-
specific mAbs alone. No increase in phosphorylation of
TCR  and ZAP-70 was seen after superagonistic CD28
stimulation whereas as expected, phosphorylation was
readily detectable by conventional costimulation via TCR
plus CD28-specific mAbs (Fig. 7 A). This indicates that
superagonistic CD28 stimulation does not address the
proximal signaling machinery of the TCR. Many genes
transcribed during T cell activation, e.g., the IL-2 gene,
are regulated by transcription factors of the NF- B family
that are activated in a costimulation-dependent manner
(3). After stimulation with superagonistic but not conven-
tional CD28-specific mAbs alone, nuclear translocation of
c-Rel (Fig. 7 B) and p50 (not depicted) was detected, as
was the case for T cell costimulation via the TCR plus
CD28. Therefore, the NF- B pathway is also activated by
superagonistic CD28 stimulation without TCR engage-
ment. These data confirm and extend our previous obser-
vations concerning superagonistic CD28 signaling in the
rat system (13).
Discussion
Soon after the first mAbs were raised against leukocyte
cell surface molecules it was realized that they could be
used to alter the course of immune responses, potentially in
a therapeutic setting (30–32). The majority of these anti-
bodies block immune functions or augment them when
Figure 4. Stimulation of human T cells by superagonistic anti-CD28 mAb in the presence and absence of TCR triggering. Freshly isolated human T
cells from PBMC were cultured at 5   105/ml in plates containing (A) or lacking (B) immobilized anti-CD3 mAb (suboptimal concentration of 0.003
 g/ml) and soluble anti-CD28 mAb7.3B6 (a representative costimulatory mAb), 9D7 or 5.11A1 (3  g/ml; two novel superagonistic mAb). (C) Titra-
tion of anti-CD28 mAb in the absence of anti-CD3 mAb. (A–C) Cells were cultured for 3 d before the addition of [3H]thymidine. Data are representa-
tive for four (A and B) or two (C) independent experiments.T
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used in conjunction with other reagents. The much smaller
subset of antibodies that activate leukocytes autonomously
are defined here as superagonists. Our present findings
show that the costimulatory receptor, CD28, can be trig-
gered by superagonists binding to a defined structural ele-
ment of the homodimer distinct from the CD80/CD86
binding site. The evolutionary conservation of this struc-
ture–activity relationship is striking: identification of the
superagonistic epitope of rat CD28 permitted an exact pre-
diction of its human counterpart based on its location.
According to a model of the human CD28 monomer
based on the CTLA-4 structure (24), residues 60–65 form-
ing the superagonist epitope are located between the C  
and D strands at the “edge” of the V-set domain (Fig. 3).
CTLA-4 is the best current model for the CD28 ho-
modimer and according to this, the C  D loop maps to the
“outside” of the dimer where it protrudes from the mem-
brane-proximal part of the V-set domain (Fig. 3). In con-
trast to the superagonists, the “classical” costimulatory
CD28-specific mAbs are critically dependent on the spe-
cies-specific aa side chain at position 98 (valine and phe-
nylalanine in the rat and mouse CD28 structures, respec-
tively), adjacent to the ligand binding MYPPPY motif
(positions 99–104; Fig. 3; reference 29).
What is the mechanistic basis for triggering by superag-
onistic C  D loop–specific mAbs and why are costimula-
Figure 5. Epitope mapping of su-
peragonistic human CD28-specific
mAb. Binding of two superagonistic
(9D7 and 5.11A1) and a conven-
tional (7.3B6) human CD28-specific
mAb to L 929 fibroblast cells ex-
pressing full-length human CD28
(top), full-length mouse CD28
(middle), and a chimeric human/
mouse CD28 molecule with a hu-
manized C”D loop (bottom). Hu-
man sequences are shown in black
and mouse sequences in white.
FACS®  histograms are shown for
9D7, 5.11A1, and 7.3B6 (solid
lines), and for an isotype-matched
control mAb (dotted lines). At least
two independent experiments were
performed and a representative ex-
periment is shown.
Figure 6. Activation of T cell hybridoma cells via superagonistic CD28-specific mAb. The 58 T cell hybridoma line supplemented with a rat TCR
was retrovirally transduced with mouse CD28 containing the following replacements: (A) the whole extracellular part of rat CD28, (B) the rat C  D loop,
or (C) the human C  D loop. The cell lines were left unstimulated or were stimulated via immobilized anti-TCR mAb R73, superagonistic CD28-spe-
cific mAb (JJ316 for rat, 5.11A1 for human) at the indicated final concentrations, ranging from 10 to 1  g/ml, or conventional CD28-specific mAb
(JJ319 for rat, 37.51 for the chimeric molecules). After 2 d, supernatants were tested for the presence of mouse IL-2 by ELISA. Because stimulation with
conventional CD28-specific mAb did not result in substantial IL-2 production at any concentration tested, only results using the highest concentration
(10  g/ml) are presented. One of at least three independent experiments with similar results is shown.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
963 Lühder et al.
tory mAbs ineffective? Four distinct mechanisms can be
considered.
Preferential Engagement of Signaling-competent CD28.
HLA class II molecules are proposed to exist in functionally
distinct microclusters identified by mAbs dependent for
binding on preexisting oligomerization of their targets (33).
The possibility that superagonistic and conventional mAbs
bind to CD28 molecules in different states of oligomeriza-
tion is suggested by our previous work showing that the
binding kinetics of superagonists seem to be slower than
those of conventional CD28-specific mAbs, suggesting that
heterogeneity exists within the population of CD28 mole-
cules (12). The slow on-rate of superagonists was dramati-
cally enhanced by simultaneous TCR stimulation, which
was in turn dependent on cytoskeletal rearrangements (as
shown by its sensitivity to cytochalasin D; reference 13). In
the framework of the “microcluster hypothesis,” this sug-
gests that TCR ligation enhances CD28 clustering and
thereby facilitates superagonist binding to preactivated
CD28 molecules. Given that the majority of CD28 mole-
cules present on the surface of resting T cells have little lat-
eral mobility and that TCR engagement appears to direct a
mobile fraction toward the central zone of the immunolog-
ical synapse along with the TCR leading to costimulatory
signaling by CD28 (6), it is possible that only the easily
mobilized CD28 molecules become signaling competent,
and then only when clustered. If this is the case, and the ac-
cessibility of the mAbs to clustered CD28 molecules is
highly epitope dependent, it is conceivable that the clusters
will be differentially mobilized by the two groups of mAbs.
Differential Cross-Linking. In humans, CD28 is only the
third T cell surface molecule or complex found to be capa-
ble of fully activating T cells upon cross-linking with anti-
body alone. For the TCR–CD3 complex (34, 35), the an-
tibodies generally need to be immobilized to achieve full
activation. CD2 is distinct insofar as it requires pairs of anti-
bodies specific for separate epitopes, but immobilization of
the antibodies is not then required (36, 37), suggesting that
the simultaneous binding of antibodies to two separate
epitopes generates a particularly high degree of cross-link-
ing and strong signaling. The CD80 homodimer is also
proposed to link bivalent CTLA-4 partners on the oppos-
ing cell surface, allowing stable, large scale lattice formation
through periodic CTLA-4–CD80 interactions (38). This is
expected to potentiate inhibitory signaling by CTLA-4,
and cross-linking of CD28 by the superagonistic mAbs
might be both structurally and functionally analogous. The
positioning of the C  D loop on the outside of the Ig-like
domains may favor bivalent mAb binding and periodic lat-
tice formation while precluding one on one binding (i.e.,
the binding of both arms of the antibody to a single CD28
homodimer). The costimulatory mAbs, on the other hand,
might be incapable of inducing this level of cross-linking.
The CD28 homodimer binds single CD80 and CD86 mol-
ecules in contrast to CTLA-4, which is bivalent (39).
Given the proximity of the epitope of the costimulatory
mAbs to the ligand binding site (Fig. 3), it is possible that at
the cell surface, the simultaneous binding of two costimula-
tory mAbs or two ligand molecules is precluded by similar
mechanisms. We note, however, that the CD28 ho-
modimer is generally bivalent for antibody binding (39).
Proximity Effects. Overall, the simple cross-linking hy-
pothesis does not completely explain the stimulatory effects
because, as for CD2 (37), ligation with nonactivating mAbs
followed by cross-linking with polyclonal anti-Fc antibody
fails to fully activate T cells. Moreover, the activating and
nonactivating mAbs in both systems clearly form distinct
activity groups defined by shared epitopes, which is not
predicted by the cross-linking model. The observation that
the effects of the antibodies are highly position dependent
suggests that the cell surface molecules may in fact be func-
tionally asymmetric, or “sided.” A similar effect may ac-
count for the agonistic and antagonistic properties of anti-
TCR antibodies, given the absence of any correlation with
binding avidity, although the epitopes of the anti-TCR
mAbs have not been mapped (40). In this case, the super-
agonistic mAbs bind in a position approximately orthogo-
nal to that of the costimulatory mAbs (Fig. 3). It is possible
that the costimulatory and superagonistic antibodies cross-
link to the same degree and that the position of the epitope
bound by the cross-linking antibody influences the prox-
imity of intracellular effector molecules, such as kinases, at-
tached to the cytoplasmic domains of the cross-linked mol-
Figure 7. Mitogenic anti-CD28 antibody stimulation activates NF- B
without inducing tyrosine phosphorylation of TCR  or ZAP-70. (A) T
cells were preincubated with the indicated stimulating antibodies for 1 h
at 4 C, washed, incubated with 10  g/ml rat anti–mouse IgG for 30 min
at 4 C, and incubated for 0.5 min at 37 C before the addition of NP-40
lysis buffer. Proteins were precipitated with antibodies to ZAP-70 and
TCR   precoupled to protein G–Sepharose, resolved by SDS-PAGE,
Western blotted, and probed with antiphosphotyrosine antibody. Mem-
branes were reprobed with antibodies to TCR  and ZAP-70 to ensure
comparable loading. (B) Nuclear extracts from the same cells stimulated
with the same primary antibodies and incubated for 20 h on sheep anti–
mouse IgG-coated plates were resolved by SDS-PAGE, Western blotted,
and probed with antibodies to c-Rel or USF-2 as a loading control.T
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ecules, thereby altering down-stream signaling processes.
This requires that the geometric positioning of the cyto-
plasmic domain, relative to the extracellular domain, is
“fixed” (i.e., that the two are unable to rotate separately).
Supporting this concept, we note that the agonist and an-
tagonist signaling properties of synthetic erythropoietin
(EPO) mimics are exquisitely sensitive to the geometry of
EPO receptor ligation (41).
Antibody-induced Conformational Changes. Conforma-
tional changes have been invoked to explain the differen-
tial effects of antibodies, most notably in the case of the
TCR (40). Synonymous, ligand-induced changes in the
 /  subunits of the TCR capable of driving signaling have
been ruled out by structural studies, however (42). Al-
though signaling roles for conformational changes in the
CD3 subunits of the TCR have been proposed (43, 44), in
neither case has the native ligand been shown to induce
analogous effects. Perhaps the best examples of conforma-
tional change-based mechanisms involve subunit organiza-
tional changes proposed for integrin heterodimers (45), the
epidermal growth factor receptor (46, 47), and the EPO
receptor homodimer (48). Leaving aside the problem of
how antibodies would induce structural changes on this
scale, it is very unlikely that similar intersubunit rearrange-
ments could be propagated to the cell interior given that
the relationship between the monomers is fixed by an in-
terchain–disulphide bond at the base of the extracellular
domain of CD28.
Overall, we favor the view that the superagonistic effects
of certain antibodies (e.g., anti-CD28 mAbs), or combina-
tions thereof (e.g., anti-CD2 mAbs), depend in the first in-
stance on the formation of cross-linked, periodic arrays of
those surface molecules capable of inducing signaling and
secondarily, on the topology of binding. CTLA-4 and
CD80, which interact with relatively high affinity, are now
thought to engage in qualitatively similar interactions (38,
49, 50). This combination of properties is unprecedented at
the cell surface, suggesting that uniquely stable, inhibitory
signaling complexes are necessary to overturn ongoing acti-
vation signals (38).
The present data clearly suggest that the cross-linking of
CD28 into periodic arrays in a similar manner generates
powerful activating signals circumventing TCR-dependent
signaling. Two distinct mechanisms appear to have evolved
to prevent the nonspecific, polyclonal activation of T cells
by CD28 via such a process. First, CD28 is rendered sub-
servient and consequential to the TCR by virtue of the de-
pendence of costimulatory signaling on immunological
synapse formation, which is itself dependent on TCR sig-
naling (6). Second, CD28 is incapable of forming ex-
tremely stable, avidity-driven ligand interactions similar to
those of CTLA-4, not only because the interactions of
CD28 are much weaker than those of CTLA-4, but also
because CD28 is monovalent and CD86 is monomeric
(39). These observations underscore the functional impor-
tance of structural distinctions between CD28 and CTLA-4
and between CD80 and CD86.
Finally, we and others have shown that the superagonists
initiate downstream signaling events including NFAT, NF-
 B, and GATA-3 translocation and, of course, proliferation
and cell cycle progression (13, 14, 51) in the absence of
TCR  or Zap70 hyperphosphorylation. Studies of the ef-
fects of conventional mAbs or B7 transfected cells have
previously shown that the modification of grb2, p62dok,
vav, and slp76 (10, 52, 53) can all occur in the absence of
TCR ligation. Superagonistic stimulation in T cell lines
nevertheless requires the presence of the TCR at the cell-
surface (unpublished data). Therefore, we favor the view
that the constitutive, low level triggering of the TCR en-
hances the recruitment of key intermediates at the point
where the signal 1 and signal 2 pathways converge or, alter-
natively, provides a sufficient amount of preactivated CD28
molecules to be addressed by superagonist stimulation. Im-
portantly, the activation of resting primary T cells with su-
peragonistic mAbs proceeds without a detectable increase
above the basal constitutive phosphorylation of ZAP-70
(Fig. 7; reference 13) or the TCR  chain (Fig. 7) excluding
indirect or cross-reactive stimulation of the TCR complex.
The effects of cross-linking by the superagonistic mAbs we
observe may therefore be mimicking the very early events
after TCR triggering and synapse formation.
The oligomerization of the CD28 homodimer via the
laterally exposed C  D loop releases the full signaling po-
tential of this key regulator of human immune responses.
This makes superagonistic CD28 mAbs unique polyclonal
T cell activators with the potential to exploit the mito-
genic, anti-apoptotic, and antiinflammatory effects associ-
ated with CD28-mediated T cell activation, and hence
promising drugs for immunotherapy. A more complete un-
derstanding of the mechanism(s) of superagonistic signaling
awaits the determination of the structure of CD28.
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